Xeris Biopharma Holdings, Inc. (XERS) — AI Hisse Senedi Analizi

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing therapies in endocrinology, neurology, and gastroenterology. Their portfolio includes treatments for severe hypoglycemia, periodic paralysis, and Cushing's syndrome, utilizing proprietary formulation technology.

Şirket Genel Bakışı

ÇOK UZUN; OKUMADIM:

Xeris Biopharma is a commercial-stage biopharmaceutical innovator delivering ready-to-use injectable therapies, including Gvoke for severe hypoglycemia, and Recorlev for Cushing's syndrome; leveraging proprietary XeriSol and XeriJect platforms to expand indications and develop novel products, addressing unmet needs in endocrinology, neurology and gastroenterology.

XERS Hakkında

Xeris Biopharma Holdings, Inc., founded in 2005 and headquartered in Chicago, Illinois, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patient populations across endocrinology, neurology, and gastroenterology. The company's mission is to improve patient lives by providing differentiated and convenient treatment options. Xeris markets Gvoke, a ready-to-use liquid glucagon injection for the treatment of severe hypoglycemia, offering a user-friendly alternative to traditional glucagon kits. Additionally, they commercialize Keveyis, a therapy indicated for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Recorlev, a cortisol synthesis inhibitor, is another key product, approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Xeris leverages its proprietary formulation technology platforms, XeriSol and XeriJect, to create stable, ready-to-use injectable formulations. These platforms enable the company to extend the utility of existing products into new indications and develop novel products, addressing unmet medical needs and improving patient outcomes. Xeris Biopharma is committed to expanding its product portfolio and pipeline through internal development and strategic partnerships.

Yatırım Tezi

Xeris Biopharma presents a notable market position due to its established commercial products, innovative technology platforms, and focus on underserved patient populations. With a market capitalization of $1.16 billion, Xeris has demonstrated its ability to successfully commercialize Gvoke, Keveyis, and Recorlev, generating revenue and establishing a foothold in the endocrinology, neurology, and gastroenterology markets. The company's proprietary XeriSol and XeriJect platforms provide a competitive advantage, enabling the development of differentiated injectable therapies. The company's gross margin of 83.5% indicates strong pricing power and efficient operations. Continued revenue growth from existing products, coupled with successful pipeline development and expansion into new indications, are key catalysts for future value creation. The company's focus on addressing unmet medical needs in specialized markets offers significant growth potential.

Sektör Bağlamı

Xeris Biopharma operates within the biotechnology industry, a sector characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for injectable therapies is growing, driven by the increasing prevalence of chronic diseases and the demand for convenient and effective treatment options. Xeris competes with other pharmaceutical and biotechnology companies, including those focused on diabetes, neurological disorders, and endocrine diseases. Competitors include companies like ABCL, BCRX, BHVN, CLDX, and HRMY. The company's proprietary technology platforms and focus on specialized markets provide a competitive edge in this dynamic landscape.

Healthcare/Biotechnology

Healthcare

Büyüme Fırsatları

Expanding Gvoke's Market Reach: Gvoke, a ready-to-use liquid glucagon, addresses a significant market need for convenient treatment of severe hypoglycemia. Xeris can further penetrate the market by expanding its sales and marketing efforts, targeting healthcare providers, patients, and caregivers. The market for glucagon products is estimated to grow, driven by the increasing prevalence of diabetes. Successful execution of this strategy could significantly increase Gvoke's revenue and market share.
Developing New Indications for Existing Products: Xeris can leverage its XeriSol and XeriJect platforms to develop new indications for its existing products, such as Keveyis and Recorlev. This strategy offers a cost-effective way to expand the company's product portfolio and address unmet medical needs in related therapeutic areas. Clinical trials and regulatory approvals are key milestones for this growth opportunity.
Advancing Pipeline Programs: Xeris has a pipeline of development programs focused on new therapies for endocrinology, neurology, and gastroenterology. Advancing these programs through clinical trials and obtaining regulatory approvals are crucial for long-term growth. Successful development and commercialization of new products will diversify the company's revenue streams and enhance its market position.
Strategic Partnerships and Acquisitions: Xeris can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. Collaborating with other pharmaceutical and biotechnology companies can accelerate the development and commercialization of innovative therapies. Identifying and executing value-creating deals is essential for this growth strategy.
Geographic Expansion: Xeris can expand its commercial operations into new geographic markets, such as Europe and Asia. This strategy will allow the company to reach a larger patient population and increase its revenue potential. Obtaining regulatory approvals and establishing distribution networks are key steps for successful geographic expansion.

Market Cap of $1.16B reflects investor confidence in Xeris's growth potential and established product portfolio.
Gross Margin of 83.5% demonstrates efficient operations and strong pricing power in the specialty pharmaceutical market.
Commercialized Gvoke, a ready-to-use liquid glucagon, addresses a critical need for convenient treatment of severe hypoglycemia.
Proprietary XeriSol and XeriJect formulation technologies provide a competitive advantage in developing stable, injectable therapies.
Focus on endocrinology, neurology, and gastroenterology aligns with growing demand for specialized treatments in these therapeutic areas.

Ne Yaparlar

Develop and commercialize therapies for endocrinology.
Develop and commercialize therapies for neurology.
Develop and commercialize therapies for gastroenterology.
Market Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia.
Market Keveyis for the treatment of primary periodic paralysis.
Market Recorlev for the treatment of Cushing's syndrome.
Utilize XeriSol and XeriJect technology platforms for drug formulation.

İş Modeli

Develop proprietary drug formulations using XeriSol and XeriJect technologies.
Commercialize and market pharmaceutical products directly to healthcare providers and patients.
Generate revenue through product sales of Gvoke, Keveyis, and Recorlev.
Pursue strategic partnerships for product development and commercialization.

Patients with severe hypoglycemia requiring glucagon treatment.
Patients with hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.
Adult patients with Cushing's syndrome.
Healthcare providers who prescribe and administer Xeris's therapies.

Proprietary XeriSol and XeriJect formulation technologies create barriers to entry.
Established commercial presence with Gvoke, Keveyis, and Recorlev.
Focus on specialized markets with unmet medical needs.
Strong intellectual property protection for its products and technologies.

Katalizörler

Upcoming: Clinical trial results for pipeline programs.
Upcoming: Regulatory approvals for new products and indications.
Ongoing: Expansion of sales and marketing efforts for Gvoke, Keveyis, and Recorlev.
Ongoing: Strategic partnerships and acquisitions.
Ongoing: Geographic expansion into new markets.

Riskler

Potential: Competition from established pharmaceutical companies.
Potential: Regulatory setbacks and delays in product approvals.
Potential: Product liability claims and litigation.
Ongoing: Dependence on key personnel.
Ongoing: Fluctuations in the biotechnology market.

Güçlü Yönler

Proprietary drug formulation technologies (XeriSol and XeriJect).
Commercialized products with established revenue streams (Gvoke, Keveyis, Recorlev).
Focus on specialized markets with unmet medical needs.
Experienced management team with expertise in drug development and commercialization.

Zayıflıklar

Negative profit margin (-5.9%).
Reliance on a limited number of products for revenue generation.
High research and development expenses.
Dependence on regulatory approvals for new products and indications.

Fırsatlar

Expanding market reach for existing products.
Developing new indications for existing products.
Advancing pipeline programs through clinical trials.
Strategic partnerships and acquisitions to expand product portfolio.

Tehditler

Competition from other pharmaceutical and biotechnology companies.
Regulatory challenges and delays.
Product liability claims.
Changes in healthcare reimbursement policies.

Rakipler & Benzerleri

AbCellera Biologics Inc. — Focus on antibody discovery and development. — (ABCL)
BioCryst Pharmaceuticals, Inc. — Develops novel small-molecule drugs. — (BCRX)
Biohaven Ltd. — Focuses on neurological and neuropsychiatric diseases. — (BHVN)
Celldex Therapeutics, Inc. — Develops antibody-based therapies. — (CLDX)
Harmony Biosciences Holdings, Inc. — Focuses on therapies for rare neurological diseases. — (HRMY)

Key Metrics

Price: $5.57 (+5.09%)
Market Cap: $961
P/E Ratio: 1668.60
Volume: NaN
MoonshotScore: 58/100

Company Profile

CEO: John Shannon
Headquarters: Chicago, IL, US
Employees: 394
Founded: 2018

AI Insight

Stock data pending update.

Sorular & Cevaplar

What does Xeris Biopharma Holdings, Inc. do?

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company that develops and commercializes innovative therapies in endocrinology, neurology, and gastroenterology. The company focuses on creating ready-to-use injectable formulations using its proprietary XeriSol and XeriJect technology platforms. Its marketed products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing's syndrome. Xeris aims to improve patient outcomes by providing differentiated and convenient treatment options for specialized medical needs.

Is XERS stock a good buy?

XERS stock presents a mixed investment profile. The company's strong gross margin of 83.5% and innovative technology platforms are positive indicators. However, the negative P/E ratio of -79.61 and negative profit margin of -5.9% raise concerns about profitability. Potential investors should carefully consider Xeris's growth opportunities, pipeline development, and competitive landscape, as well as the risks associated with the biotechnology industry, before making an investment decision. Monitor upcoming clinical trial results and regulatory approvals for potential catalysts.

What are the main risks for XERS?

Xeris Biopharma faces several risks, including competition from established pharmaceutical companies, regulatory challenges and potential delays in product approvals, and the possibility of product liability claims. The company's reliance on a limited number of products for revenue generation also poses a risk. Additionally, fluctuations in the biotechnology market and changes in healthcare reimbursement policies could negatively impact Xeris's financial performance. Investors should carefully assess these risks before investing in XERS stock.

Is XERS a good investment right now?

Use the AI score and analyst targets on this page to evaluate Xeris Biopharma Holdings, Inc. (XERS). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for XERS?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Xeris Biopharma Holdings, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find XERS financial statements?

Xeris Biopharma Holdings, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about XERS?

Analyst consensus targets and ratings for Xeris Biopharma Holdings, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is XERS stock?

Check the beta and historical price range on this page to assess Xeris Biopharma Holdings, Inc.'s volatility relative to the broader market.